PFE
US EQUITY
Health Care
Pharmaceuticals
CIK: 78003
Pfizer (PFE) Quant Factor Diagnostic & Fair Value Model
Pfizer (Ticker: PFE) is listed in the Health Care sector (Pharmaceuticals). Below is its point-in-time financial profile, valuation multiples, and cross-sectional factor diagnostics.
$30.03
-1.28%
Latest Close (2026-10-23)
Market Cap: $171.16B
P/E Ratio: 39.5
Momentum Strength
3M / 12M
+21.73%
1M: +5.70%
12M: +21.48%
Quality (ROE)
Point-in-Time
-1.16%
Trailing Return on Equity
Technical Trend
RSI 14
78.3
SMA50: $28.30
SMA200: $26.68
Valuation Multiplier
Trailing
39.5
Premium Multiple (> 30x P/E)
📊
Valuation & Multi-Factor Diagnostic
Premium Multiple (> 30x P/E)
PFE trades at 39.5x P/E, reflecting market-implied growth expectations for forward revenue and cash flow.
⚡
Benchmark Factor Strategy
S&P 500 Momentum Alpha Strategy
This strategy applies cross-sectional momentum and quality factor filters across large-cap US equities.
📈 Daily Candlestick & Volume Quant Chart
Interactive lightweight price action & volume breakdown over recent 90 trading days.
均线多头 (MA20/50)
Piotroski F-Score: 5/9 (Moderate Financial Health)
Official Point-in-Time Financial Filing History
Zero Lookahead Bias: Every financial metric is timestamped at the exact moment officially published to the market.
备案 CIK: 78003 · 10-K 年报 / 10-Q 季报
| Form | Period End | Filing Timestamp (Point-in-Time) | Revenue | Net Income | Operating CF | EPS (Diluted) |
|---|---|---|---|---|---|---|
| 10-Q | 2026-06-28 | 2026-08-04 | $15.03B | -$248.00M | $3.45B | $-0.04 |
| 10-Q | 2025-12-31 | 2026-08-04 | - | - | - | - |
| 10-Q | 2025-06-29 | 2026-08-04 | $14.65B | $2.91B | $1.75B | $0.51 |
| 10-Q | 2026-03-29 | 2026-05-05 | $14.45B | $2.69B | $2.62B | $0.47 |
| 10-Q | 2025-03-30 | 2026-05-05 | $13.71B | $2.97B | $2.33B | $0.52 |
| 10-K | 2025-12-31 | 2026-02-26 | $62.58B | $7.77B | $11.70B | $1.36 |
| 10-K | 2024-12-31 | 2026-02-26 | $63.63B | $8.03B | $12.74B | $1.41 |
| 10-K | 2023-12-31 | 2026-02-26 | $59.55B | $2.12B | $8.70B | $0.37 |
💡 Methodology & Frequently Asked Questions
Key reference details regarding Pfizer (PFE) valuation multiples, momentum factors, and point-in-time filing conventions.
How should PFE's current valuation multiple be interpreted? ↓
PFE trades at a trailing P/E of 39.5x within the Health Care sector (premium multiple (> 30x p/e)). Valuation multiples are computed using trailing-twelve-month GAAP earnings against the latest close price.
What are PFE's key momentum and technical factor indicators? ↓
As of the latest close, PFE shows a 1-month return of +5.70%, 3-month return of +21.73%, and 12-month return of +21.48%, with a 14-day RSI of 78.3. Momentum factors reflect short- and intermediate-term price velocity across the equity cross-section.
What is Point-in-Time (PIT) financial data and why does it matter for PFE? ↓
Point-in-Time indexing aligns corporate fundamentals with their official public filing timestamps (Form 10-Q/10-K) rather than accounting period-end dates. This methodology eliminates lookahead bias in historical equity backtests.
How can PFE be incorporated into systematic factor models? ↓
PFE can be evaluated within customized multi-factor models or screened against cross-sectional filters (such as momentum quintiles and return on equity) to analyze historical turnover and risk-adjusted return.